PTEN Protein Loss Is More Frequent in ERG-Positive Prostate Tumors

被引：0
|
作者：
Lotan, T. L.
Chaux, A.
Peskoe, S.
Hicks, J.
Platz, E. A.
Netto, G. J.
De Marzo, A. M.
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[2] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA
来源：
LABORATORY INVESTIGATION | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
959
引用
收藏
页码：231A / 231A
页数：1
相关论文
共 50 条
  • [11] ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
    Furusato, B.
    Tan, S-H
    Young, D.
    Dobi, A.
    Sun, C.
    Mohamed, A. A.
    Thangapazham, R.
    Chen, Y.
    McMaster, G.
    Sreenath, T.
    Petrovics, G.
    McLeod, D. G.
    Srivastava, S.
    Sesterhenn, I. A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (03) : 228 - 237
  • [12] PTEN LOSS AND ERG EXPRESSION IN PROSTATE CANCER SURVIVAL
    Ahearn, Thomas
    Pettersson, Andreas
    Ebot, Ericka
    Gerke, Travis
    De Morais, Carlos
    Hicks, Jessica
    Wilson, Kathryn
    Rider, Jennifer
    Fiorentino, Michelangelo
    Finn, Stephen
    Giovannucci, Edward
    Loda, Massimo
    Stampfer, Meir
    De Marzo, Angelo
    Mucci, Lorelei
    Lotan, Tamara
    JOURNAL OF UROLOGY, 2015, 193 (04): : E59 - E60
  • [13] ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification
    B Furusato
    S-H Tan
    D Young
    A Dobi
    C Sun
    A A Mohamed
    R Thangapazham
    Y Chen
    G McMaster
    T Sreenath
    G Petrovics
    D G McLeod
    S Srivastava
    I A Sesterhenn
    Prostate Cancer and Prostatic Diseases, 2010, 13 : 228 - 237
  • [14] Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells
    Mohamed, Ahmed A.
    Tan, Shyh-Han
    Xavier, Charles P.
    Katta, Shilpa
    Huang, Wei
    Ravindranath, Lakshmi
    Jamal, Muhammad
    Li, Hua
    Srivastava, Meera
    Srivatsan, Eri S.
    Sreenath, Taduru L.
    McLeod, David G.
    Srinivasan, Alagarsamy
    Petrovics, Gyorgy
    Dobi, Albert
    Srivastava, Shiv
    MOLECULAR CANCER RESEARCH, 2017, 15 (10) : 1308 - 1317
  • [15] Determination of Intratumoral Heterogeneity for PTEN Loss in Prostate Cancer by IHC for PTEN and ERG
    Ocal, B. Gumuskaya
    Gurel, B.
    Hicks, J. L.
    Lotan, T.
    De Marzo, A. M.
    LABORATORY INVESTIGATION, 2012, 92 : 210A - 210A
  • [16] Determination of Intratumoral Heterogeneity for PTEN Loss in Prostate Cancer by IHC for PTEN and ERG
    Ocal, B. Gumuskaya
    Gurel, B.
    Hicks, J. L.
    Lotan, T.
    De Marzo, A. M.
    MODERN PATHOLOGY, 2012, 25 : 210A - 210A
  • [17] TMPRSS2-ERG and PTEN loss in prostate cancer
    Jeremy A Squire
    Nature Genetics, 2009, 41 : 509 - 510
  • [18] TMPRSS2-ERG and PTEN loss in prostate cancer
    Squire, Jeremy A.
    NATURE GENETICS, 2009, 41 (05) : 509 - 510
  • [19] Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer
    Bjorkman, Mari
    Iljin, Kristiina
    Halonen, Pasi
    Sara, Henri
    Kaivanto, Elisa
    Nees, Matthias
    Kallioniemi, Olli P.
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (12) : 2774 - 2781
  • [20] A 36-gene Signature Predicts Clinical Progression in a Subgroup of ERG-positive Prostate Cancers
    Tandefelt, Delila Gasi
    Boormans, Joost L.
    van der Korput, Hetty A.
    Jenster, Guido W.
    Trapman, Jan
    EUROPEAN UROLOGY, 2013, 64 (06) : 941 - 950
12345